Evidence map›Paper›PMID 42522160›Full record

ArticleClinical pharmacology and therapeutics2026

Sustainability in Pharmaceutical Research and Development: A Perspective on Opportunities for Clinical Pharmacology and Translational Sciences.

Nikolas Onufrak, Karthik Venkatakrishnan

Abstract read
In one paragraph

Article in Clinical pharmacology and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Nikolas OnufrakEMD Serono, Billerica, Massachusetts, USA.
Karthik VenkatakrishnanEMD Serono, Billerica, Massachusetts, USA.ORCID 0000-0003-4039-9813

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With society's rising concern over resource expenditures, sustainable solutions are sought across industries. The pharmaceutical research & development (R&D) enterprise faces the dual challenge of navigating the complexity of human disease and a highly regulated environment, leading to extensive data generation to ensure patient-focused development of optimal therapeutics. Through innovative study designs, translational technologies, and model-informed approaches, clinical pharmacology as a discipline can meaningfully contribute to reducing drug development's carbon footprint and achieving sustainability goals.

Indexed as

Drug DevelopmentDrug DiscoveryDrug IndustryPharmaceutical ResearchPharmacology, ClinicalTranslational Research, BiomedicalTranslational Science, BiomedicalHumans

Identifiers

PMID42522160
PMCPMC13415901

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.